PCSK9 and peripheral arterial disease: “Loss-of-function” mutations, for example PCSK9 R46L (rs11591147), were associated with lower circulating LDL-cholesterol levels through increased LDLR levels, resulting in a lower prevalence of peripheral arterial disease and a reduced risk of coronary heart disease [52].